Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection (PREPCOV)
COVID-19
About this trial
This is an interventional other trial for COVID-19 focused on measuring lupus erythematous disease, prophylaxis, pre-emptive therapy, Hydroxy-Chloroquine
Eligibility Criteria
Inclusion Criteria:
Group with hydroxychloroquine treatment (HC +):
- LED/SG diagnosed
- Treatment with Hydroxy-Chloroquine in the 3 months before and during the outbreak at COVID 19, at least in December 2019. Patients may have treatment with immunosuppressants in combination with Hydroxy-Chloroquine.
- COVID19 diagnostic questionnaire and available serology result.
Group without hydroxychloroquine treatment (HC-) :
No Hydroxy-Chloroquine intake for more than 12 months
--> HC- without an immunosuppressant
- Viral hepatitis C cured for more than 12 months or primitive bile cholangitis (CBP) whose diagnosis is based on international criteria.
- Non-significant liver fibrosis assessed either by historical histology or by fibroscan with non-significant liver fibrosis Metavir - F3 (at last available examination)
- No Hydroxy-Chloroquine, or immunosuppressants have been taken for more than 12 months.
COVID19 diagnostic questionnaire and COVID19 serology result available.
-->HC- with an immunosuppressant
- Diagnosis of LED/SG according to the CAB criteria revised in 1997 or autoimmune hepatitis according to the international criteria validated in 2008.
- Patients treated with immunosuppressants for at least three months before the start of the pandemic at COVID 19, at least since December 2019.
- COVID19 diagnostic questionnaire and available serology result.
Exclusion Criteria:
- Anti-CD20 or Cyclophosphamide taken during the six months prior to the completion of the COVID 19 serology.
- Refusal of a blood test for antibodies to COVID-19.
- Protected adults
- Pregnant or breastfeeding women.
- Lack of health insurance coverage
Sites / Locations
- Limoges university Hospital
- Montpellier University Hospital
- Pitié Salpêtrière Hospital - Hépatologie
- Pitié Salpêtrière Hospital - Médecine interne
- Haut-Lévêque Hospital - Gastro-entérologie
- Haut-Lévêque Hospital - Médecine interne
- Joseph Ducuing Hospital - Médecine interneRecruiting
- Toulouse university Hospital - Larrey DermatologieRecruiting
- Toulouse University Hospital - RhumatologieRecruiting
- Toulouse University HospitalRecruiting
- University Hospital of Toulouse - Rangueil Médecine interneRecruiting
- University hospital Toulouse - Purpan Médecine interneRecruiting
Arms of the Study
Arm 1
Arm 2
Other
Other
Patient treated with Hydroxy-chloroquine
Patient without treatment with Hydroxy-chloroquine
patients treated with Hydroxy-Chloroquine (HC) with or without immunosuppressants (IS)(HC+ group, n=400)
patients without treatment with Hydroxy-Chloroquine with or without immunosuppressants